Assessing the Clinical Benefit of Molecular Profiling in Patients With Solid Tumors
Reason given: Sponsor's discretion to termination due to business decision.
Key facts
- Where
- Allentown, Birmingham, Broomfield, Burnsville, Chapel Hill, Coon Rapids, Denver, Edina, Greenville, High Point, Houston, Kettering, La Crosse, Lake Charles, Lexington, Madison, Maplewood, Marshfield, Midlothian, Milwaukee, Minneapolis, New Orleans, Newark, Pasadena, Portland, Raleigh, Robbinsdale, Rockford, Rockville, Saint Louis Park, Tacoma, Tupelo, Vallejo, Waukesha, and Woodbury, United StatesSee the 40 sites
Where in United States
- Lehigh Valley Health NetworkAllentown, United StatesNo longer taking part
- University of Alabama BirminghamBirmingham, United StatesNo longer taking part
- SCL HealthBroomfield, United StatesNo longer taking part
- Minnesota Oncology - BurnsvilleBurnsville, United StatesNo longer taking part
- University of North Carolina, Chapel HillChapel Hill, United StatesNo longer taking part
- Minnesota Oncology - Coon RapidsCoon Rapids, United StatesNo longer taking part
- Kaiser Permanente ColoradoDenver, United StatesNo longer taking part
- Fairview Southdale HospitalEdina, United StatesNo longer taking part
- Bon Secours St. FrancisGreenville, United StatesNo longer taking part
- Prisma Health Cancer InstituteGreenville, United StatesNo longer taking part
- Hayworth Cancer CenterHigh Point, United StatesNo longer taking part
- UTHealth - Memorial Hemann Cancer InstituteHouston, United StatesNo longer taking part
- Kettering Health NetworkKettering, United StatesNo longer taking part
- Gundersen Health SystemLa Crosse, United StatesNo longer taking part
- Christus HealthLake Charles, United StatesNo longer taking part
- Baptist HealthLexington, United StatesNo longer taking part
- University of WisconsinMadison, United StatesNo longer taking part
- Minnesota Oncology - Maplewood Cancer CenterMaplewood, United StatesNo longer taking part
- St. John's HospitalMaplewood, United StatesNo longer taking part
- Marshfield ClinicMarshfield, United StatesNo longer taking part
- Bon Secours MidlothianMidlothian, United StatesNo longer taking part
- Aurora Research InstituteMilwaukee, United StatesNo longer taking part
- Metro-Minnesota Community Oncology Research ConsortiumMinneapolis, United StatesNo longer taking part
- Minnesota Oncology MinneapolisMinneapolis, United StatesNo longer taking part
- Regions HospitalMinneapolis, United StatesNo longer taking part
- Ochsner Clinic FoundationNew Orleans, United StatesNo longer taking part
- Christiana Care Health SystemNewark, United StatesNo longer taking part
- Kaiser Permanente Southern CaliforniaPasadena, United StatesNo longer taking part
- Kaiser Permanente NorthwestPortland, United StatesNo longer taking part
- UNC Rex HealthcareRaleigh, United StatesNo longer taking part
- North Memorial Health CareRobbinsdale, United StatesNo longer taking part
- SwedishAmericanRockford, United StatesNo longer taking part
- Kaiser Permanente - Mid-AtlanticRockville, United StatesNo longer taking part
- Minnesota Oncology - EdinaSaint Louis Park, United StatesNo longer taking part
- Park Nicollet Health ServicesSaint Louis Park, United StatesNo longer taking part
- MultiCareTacoma, United StatesNo longer taking part
- North Mississippi Medical CenterTupelo, United StatesNo longer taking part
- Kaiser Permanente Northern CaliforniaVallejo, United StatesNo longer taking part
- ProHealth CareWaukesha, United StatesNo longer taking part
- Minnesota Oncology - Woodbury ClinicWoodbury, United StatesNo longer taking part
Trial details
- Who runs it
- Strata Oncology
- Trial code
- NCT03061305
- Record updated
- 31 January 2025
- Original description
Many patients are treated for advanced cancer without knowledge of underlying molecular features that might indicate FDA approved therapies or potential eligibility for biomarker-selected clinical trials.Read full original descriptionShow less
An Observational Trial Assessing the Clinical Benefit of Molecular Profiling in Patients With Solid Tumors
Many patients are treated for advanced cancer without knowledge of underlying molecular features that might indicate FDA approved therapies or potential eligibility for biomarker-selected clinical trials.
The Strata Trial (STR-001-001) has been initiated by Strata Oncology to evaluate the clinical benefit of systematic comprehensive genomic profiling for participants with advanced cancer using real-world data and endpoints, while assessing the proportion of participants available for clinical trials and approved targeted therapies in advanced and/or aggressive cancers. The Strata Trial uses surplus, or leftover, tumor specimens for molecular profiling and does not require additional study-specific procedures.
Inclusion: Subjects must be ≥ 18 years of age; Subjects must have histologically documented solid tumors (including lymphoma and multiple myeloma); Specific criteria for individual tumor types are as follows:; Participants with gliomas are eligible at any stage of disease; Participants with pancreatic carcinoma are eligible at any stage of disease; Participants with rare tumors (i.e. cancer started in an unusual place in the body, it is unusual type and requires special treatment) are eligible at stages II-IV; Participants with other tumor types must have recurrent, relapsed, refractory, metastatic, or advanced stages III or IV cancer; Participants with other tumor types must have recurrent, relapsed, refractory, metastatic, or advanced stages III or IV cancer; Must have an adequate formalin-fixed paraffin-embedded tumor specimen for genomic sequencing.